The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Multiple Solid Tumors
Shots:
- The USPTO has issued a Notice of Allowance to the patent application covering ibudilast as a prevention of metastasis in solid tumors incl. pancreatic, lung, breast, colorectal, & ovarian cancer as well as melanoma; patent once issued will protect it until Jul 2042
- The allowed claims cover ibudilast’s use in addition to CT, immunotx., radiotherapy, photodynamic therapy, epigenetic therapy, liver-directed therapy & others plus its oral administration, various doses, distinct dosing frequencies & treatment periods
- Ibudilast, a small molecule, targets PDE4 & inflammatory cytokines. It is under development for neurodegenerative diseases (incl. ALS, progressive MS & DCM), glioblastoma, long COVID, CIPN, substance use disorder & ARDS
Ref: MediciNova | Image: MediciNova
Related News:- The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Eye Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
MediciNova
Ibudilast
MN-166
Solid Tumor
Regulatory
USPTO
Patent
Notice of Allowance
Pancreatic Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Ovarian Cancer
Melanoma
Small Molecule
metastasis
radiotherapy
photodynamic therapy
epigenetic therapy
Phosphodiesterase-4
inflammatory cytokines
neurodegenerative diseases
glioblastoma
COVID
cipn
ards
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
